Clinical Trial Update: Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating BMS-232632, a protease inhibitor, in combination with other HIV drugs has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BMS-232632

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 2 | Status: COMPLETED